Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2021

View Archived Issues

Mutations in TP73 cause lissencephaly and impaired mucociliary clearance

YishengBio cleared in UAE to conduct phase I study of PIKA recombinant COVID-19 vaccine

MUSK-targeting agonist antibody is protective against experimental congenital myasthenia

Kymera Therapeutics STAT3 degradation inducers demonstrate preclinical activity

Sumitomo Dainippon Pharma divulges 5-HT2A and/or 5-HT7 receptor antagonists

Positive topline data reported from phase II REDWOOD-HCM study of CK-274

Sitryx Therapeutics presents new NFE2L2 activators

Angex Pharmaceutical synthesizes new mTOR inhibitors

SRI International describes lipoxygenase inhibitors

iOnctura initiates clinical development of next-generation autotaxin inhibitor IOA-289

DSMB recommends continued treatment in phase II portion of OVATION 2 study with GEN-1

Prometheus initiates phase II ARTEMIS-UC study of PRA-023

Loss-of-function variant in SUV39H2 identified in autism spectrum disorder

VX-548 enters phase II development for the treatment of acute pain

CXCL9 levels predict future cardiac aging and vascular dysfunction

GS-9822 retargets integration sites and induces deep latent state in vitro

Modulation of STAT pathway with HODHBt improves NK cell cytotoxicity

Acumen initiates phase I study of ACU-193 in mild cognitive impairment or mild Alzheimer's

Lenacapavir confers viral suppression by week 16 in HIV-infected patients

Grant supports clinical development of ISA-104 for chronic hepatitis B